Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
Accelerate to discover
Related topics
Vizgen webinar: spatial relationships in Developmental Biology
Nov 21, 2023
MERFISH integrates spatial transcriptomics technology with high resolution spatial imaging, In this webinar we will...
Nov 14, 2023
The xCELLigence RTCA eSight enables simultaneous real time biosensor impedance-based and...
NanoCellect webinar: Plant Potential - Gentle Cell Sorting for Enhanced Plant Biology Workflows
Nov 3, 2023
Gentle cell sorting is a useful tool to increase the efficiency of plant biology workflows that include gene...
Single Cell Deposition: the cornerstone of Flow Cytometry for cellular analysis and manipulation
Nov 2, 2023
One notable technology for harnessing the power of single cell deposition is the NanoCellect WOLF G2 Cell Sorter and N1...
Emulate in vivo conditions – introduce shear flow to your experiments with BioFlux system
Oct 31, 2023
Most research is still conducted in vitro without the presence of flow. We use the BioFlux System to give you the...
Single Cell Deposition: the cornerstone of Flow Cytometry for cellular analysis and manipulation
Oct 30, 2023
One notable technology for harnessing the power of single cell deposition is the NanoCellect WOLF G2 Cell Sorter and N1...
Validation of an orthotopic non-small cell lung cancer mouse model to use in radiotherapy studies
Oct 30, 2023
The use of pre-clinical orthotopic mouse models is essential for the development of novel therapies targeting solid...
Atypical Teratoid Rhabdoid Tumours Are Susceptible to Panobinostat-Mediated Differentiation Therapy
Oct 20, 2023
To assess tumour growth, mice were imaged using the AMI-HTX bioluminescent imaging system (Spectral Instruments...
Aug 7, 2018
LSD1 is a flavin adenine dinucleotide (FAD)-dependent homolog of the amine oxidase family and there was recently brought attention to it as a potential therapeutic target. The interest came from an observation of unusually high expression of LSD1 in certain types of poor-prognosis cancers. It was previously thought that LSD1 removes monomethyl and dymethyl histone marks. However, recently it was showed that it interacts with multiple transcripton factor. This raised a possibility of other drugs being used.
New inhibitor ORY-1001 was succesfully tested on LSD1 and blast cell differentioation was observed. The flow cytometric testing on this experiment was done with Novocyte. ORY-1001 disrupts the protein interaction between LSD1 and GFI1.
Related technologies: Conventional flow cytometry
Get more info
Brand profile
Agilent provides xCELLigence impedance-based, label-free, real time cell analysis system and NovoCyte flow cytometers.
More info at:
www.aceabio.com